52 results about "Blood cancer" patented technology

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

Clonal strains of vaccinia viruses are provided. Also provided are methods of identifying and isolating attenuated and oncolytic clonal strains from virus preparations, Modified recombinant forms of the clonal strains also are provided. The clonal strains and virus preparations can be used for diagnostic and therapeutic methods, in particular for therapy and diagnosis or monitoring treatment of proliferative disorders, including neoplastic diseases, such as, but are not limited to, solid tumors and blood cancers.

A tetrahydroindolone derivative and its use are disclosed. It can inhibit malignant tumor cell growth. It can be used for mammary gland cancer, lung cancer, uterus neck cancer, rectum cancer, liver cancer and blood cancer.

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

Based on an anti-ICAM3 antibody obtained by immunizing a mouse with BaF3 cells having artificially over-expressed ICAM3, a chimeric antibody has been successfully prepared which exerts cytotoxic actions, including both a proliferation-suppressing activity and an ADCC activity, on a blood cancer cell line, and which exerts a tumor regression activity in vivo.

The present invention relates to heteroaryl compounds comprising nitrogen and use thereof, and more specifically to compounds which exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient.The compounds according to the present invention exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer with a reduced dose compared to that of existing drugs. Accordingly, the compounds can be effectively used for treating various types of cancer, such as uterine cancer, breast cancer, gastric cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, and liver cancer, and for inhibiting proliferation of cancer cells and metastasis of cancer.

The invention provides a double-site irreversible Brutons tyrosine kinase inhibitor, a drug combination containing the same and application thereof to the anti-tumor field. The compound provided by the invention has an anti-proliferation inhibiting effect to tumor cell stains such as A549, SGC7901, MCF-7, PC-9 and HL-60, and can be applied to drugs for treating solid tumors or blood cancers related to human or animal cell proliferation; the compound provided by the invention has a better pharmacokinetic property and can be applied to treating solid tumors or blood cancers related to human or animal cell proliferation or autoimmune diseases through oral taking; the compound provided by the invention has a double-site response characteristic.

The invention discloses an application of a compound as a JAK-STAT3 signal passage inhibitor, and particularly relates to an application of a compound with a formula I or pharmaceutically acceptable salt of the compound in the process of preparing an anti-tumor medicament. The application provides a novel treating candidate medicament for a tumor patient, thereby probably further improving the treatment effect on the patient and improving the prognosis of the patient. The compound with the formula I or the pharmaceutically acceptable salt of the compound has the effect on various tumor cells, which indicates that the compound can be used for treating various cancers including cerebral tumor, genitourinary system tumor, lymphatic system tumor, stomach cancer, laryngeal cancer, nasopharyngeal cancer, skin cancer, bone cancer, blood cancer, leukemia, breast cancer and histiocytic lymphoma, non-small cell lung cancer, small-cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, pancreatic cancer, prostatic cancer, liver cancer, epithelial cell cancer and the like. The definition of genes in the formula refers to description for details.

Hypoxia activated prodrugs, such as, e.g., TH-281, TH-302, and TH-308, are useful for the treatment of various blood cancers, such as acute leukemias, chronic leukemias, MDS, MF, and multiple myeloma.

Investigation on the frequency of FLT3 / ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3 / ITD in the blood cell lines revealed that the tyrosine residues in FLT3 / ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3 / ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3 / ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3 / ITD functions as an index.

The present invention relates to the use of a compound of formula 3 or a salt thereof to prepare a medicament or phototherapeutic agent for treating the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; SARS virus infection; coronavirus Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers, including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophageal cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary tract cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancer. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of the compound of formula 3 or a salt thereof to prepare a photodiagnostic agent for detecting the above-mentioned diseases and the following diseases, including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infections, viral infections, chlamydial infections, bacterial infections, or parasitic diseases, HIV viral infections, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease, and skin diseases. The present invention also relates to methods for detecting the above diseases using photodiagnostic agents. The present invention further relates to a method for low-temperature sterilization of surgical devices or other devices, including the steps of: providing a compound of Chemical Formula 3 or a salt thereof on the device; and subjecting the device to radiation treatment or sonication treatment. The invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The invention also relates to the use of such MRI enhancers for performing MRI scans.

The invention provides a poly(ADP-ribose) polymerase inhibitor as well as a preparation method and application thereof. The poly(ADP-ribose) polymerase inhibitor is a compound shown in a formula I in the specification or pharmaceutically acceptable salts, hydrates or solvates of the compound, wherein R1 is selected from hydrogen and halogens such as F, Cl, Br or I; R2 and R3 are respectively and independently selected from methyl, ethyl or naphthenic bases with 3-6 carbon atoms; and n is 1 or 2. By adopting the poly(ADP-ribose) polymerase inhibitor provided by the invention, poly(ADP-ribose) polymerases can be effectively inhibited, so that the poly(ADP-ribose) polymerase inhibitor can be used for preparing medicines for preventing and / or treating inflammations or cancers such as colon cancer, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, uterus cancer, liver cancer, gastric cancer, skin cancer, blood cancer or prostatic cancer.

The invention belongs to the technical field of medicines, and particularly relates to a tyrosine kinase inhibitor for nitrogen hetero-aromatic ring and derivatives thereof shown in the general formula (I), and pharmaceutically acceptable salts or stereoisomer thereof, wherein R1, R2, R3, L1, L2, a, b, c, d, e, p, q, A and B are defined in the specification. The invention further relates to a preparation method for the compounds, and pharmaceutical preparations containing the same, and the compounds play an important role in preparing drugs for preventing and / or treating blood cancers (such as B cell chronic lymphocytic leukemia, non-hodgkin lymphomas and the like) related to B cells, and autoimmune diseases (such as thrumatoid arthritis, systemic lupus erythematosus and the like).

The invention discloses application of a cyclohexane dicarboxylic acid derivative with a bridged ring as shown in a general formula (I), a stereoisomer and a pharmaceutically acceptable salt in preparation of anti-tumor drugs. The compounds particularly have an obvious inhibition effect on leukemia, liver cancer, lung cancer, gastric cancer and ovarian cancer. The compounds provided by the invention have high anti-tumor activity, wide anti-tumor spectrum and low toxicity, and are suitable for preparing anti-cancer drugs.

The invention provides a kit for detecting lymphoid blood cancers such as T / B leukemia, lymphoma and myeloma minimal residual diseases based on research and development of high-throughput sequencing.The kit comprises multiplex-PCR primer sets for detecting IGH(VDJ), IGH(DJ), IGK, IGL, TCRbeta, TCRgamma, TCRdelta, BCL1 / IGH and BCL2 / IGH and with UMB (Unique Molecular Barcode, single-molecular labels), House Keeping gene PCR primer pairs, Multiplex PCR Mix(2X), internal reference DNA, Nuclease-Free Water, Elution Buffer, and primers and label sequences required for high-throughput sequencing. Bythe adoption of the kit, newly-mutant cancer cells can be found while the cancer cells are detected, the high-throughput sequencing technology is applied and combined with bioinformatic analysis, forthe detection sensitivity of MRD, one cancer cell can be at least detected in 1 million cells, that is to say, the probability is 10<-6>(0.0001%), the purpose of detecting the minimal residual diseases through quantitative analysis of the number of the cancer cells can be achieved, and sequence reading errors generated in the sequence mutation and library sequencing process due to base group mismatch during PCR amplification can be corrected.

The invention provides an application of anacardic acid in preparing anti-angiogenic drugs. The anti-angiogenic drugs prepared from anacardic acid of the invention can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissueangiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of anacardic acid and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and some blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The present invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders) related to hedgehog signaling.

A microwave therapy apparatus and method for blood cancer treatment is disclosed. The microwave therapy apparatus for blood cancer treatment includes a plurality of porous anodic aluminum oxide (AAO) filters or a plurality of porous glass filters provided in a dialyzer of a hemodialysis apparatus; a nanoflower filter provided downstream of the plurality of porous anodic aluminum oxide (AAO) filters or the plurality of porous glass filters in the blood tube; and an RF absorber provided downstream of the nanoflower filter to attract cancer cells thereto by generating a frequency of a predetermined band, wherein the blood, from which the cancer cells have been removed by an RF frequency and which includes normal blood cells that passed through the nanoflower filter, is circulated and supplied to a blood tube connected to a vein of the body of the blood cancer patient.

Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes (“phosphaplatin compounds”), especially (R,R)1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or “PT-112”), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.

A 1,3-bis[N-[N-(2-methoxy)phenyl]piperazinyl]-1-acetone hydrochloride, its preparing process, and its application in preparing medicine for treating blood cancer are disclosed.

Provided are methods for reducing haematocytes in an individual. The method involve administering to an individual a composition that contains recombinant a2,6-sialyltransferase (ST6Gal I). The method is suitable for prophylaxis and therapy of a condition that is positively correlated with undesirable hematopoiesis. Such conditions include autoimmune diseases, transplantation rejection, blood cancers and allergic reactions and inflammations. The invention also provides a pharmaceutical preparation that contains recombinant ST6Gal I and which is suitable for administration to an individual to reduce haematocytes in the individual, and a pharmaceutically acceptable carrier.

The invention discloses a cyclic peptide compound or a pharmaceutically acceptable salt, ester, solvates, prodrugs, racemate or isomers thereof, and a medical composition containing the compound as aneffective component. Experiments indicate the activity of the cyclic peptide compound or the pharmaceutically acceptable salt, ester, solvate, prodrugs, racemate or isomers thereof in inhibition of aPD1 / PDL1 pathway, and the invention also discloses an application of the compound to preparation of drugs for preventing and treating tumors taking the PD1 / PDL1 pathway as a target point. The tumorscomprise blood cancers, nervous system cancer, gastrointestinal cancer, esophageal cancer, urinary system cancer, lung cancer, liver cancer, skin cancer and the like.

Investigation on the frequency of FLT3 / ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3 / ITD in the blood cell lines revealed that the tyrosine residues in FLT3 / ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3 / ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3 / ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3 / ITD functions as an index.

The present invention relates to: a novel antibody or an antigen-binding fragment thereof for use in the treatment of cancer by targeting B cell malignancies; a chimeric antigen receptor comprising the same; and uses thereof. The antibody of the present invention is an antibody specifically binding to CD19 highly expressed in cancer cells (particularly, blood cancer) and has very low homology compared to the CDR sequences of conventional CD19 target antibodies, and thus the sequence thereof is unique. In addition, cells expressing a chimeric antigen receptor comprising an anti-CD19 antibody orantigen-binding fragment of the present invention induce immune cell activity in response to a positive cell line expressing CD19, and thus can be usefully used as a therapeutic agent for CAR-immunecells.

The invention relates to coarse cereal biscuits having special treatment effects on treatment of blood cancer (leukaemia) and lymphosarcoma and having the efficacy of nourishing the brain. The coarsecereal biscuits comprise a cephalotaxus fortunei concentrated solution, wheat flour, white granulated sugar, oat flour, peanut powder, apricot kernel powder, walnut powder, vegetable oil, fructus perillae oil, celery seed oil, fresh hen eggs, sorghum flour, buckwheat powder, pumpkin powder, konjac fine powder, mung bean powder, fresh henon bamboo leaves, fresh cream, baking soda, salt and an appropriate amount of water. According to the coarse cereal biscuits provided by the invention, the usage amount of fat is reduced, and a large quantity of coarse food grain components are added, so that nutrient components of the biscuits can be enriched, after being eaten for a long term, the coarse cereal biscuits can adjust the stomach, and besides, the coarse cereal biscuits have certain effects of reducing internal heat and reducing blood pressure; the henon bamboo leaf components are added to the biscuits, so that the taste of the biscuits can be improved, the coarse cereal biscuits have theefficacy of improving sleep, and the nutrient value of the biscuits can be increased; and the cephalotaxus fortunei concentrated solution is added, so that products have multiple medical care health-care effects of preventing cancer, resisting cancer, resisting irradiation, reducing blood lipid and blood sugar, resisting ageing and the like.

The invention discloses a formula of a Hui nationality traditional Chinese medicine cordyceps sinensis blood cancer rehabilitation tablet and a preparation method thereof. The tablet belongs to a green high-tech Chinese herbal medicine for treating leukemia, belongs to a traditional Chinese medicine tablet formed by mixing Chinese herbal medicines, such as herba sarcandrae, 30 g of radix sophorae tonkinensis, pseudobulbus cremastrae seu pleiones and radix isatidis according to a certain ratio, boiling with water, extracting, concentrating and tabletting, mainly treats leukemia, also treats digestive system cancers, such as a pharyngolaryngeal cancer, a stomach cancer and a colorectal cancer, and has the characteristics that drugs are tasteless, the dosage is moderate, selected drugs are proved, through modern medical pharmacological experiments, to be capable of treating cancers, and through adoption of the tablet, the physical function is fundamentally improved at low cost, the deterioration of diseases is controlled, and health is regained.